Study of transformed splenic marginal zone lymphoma genetics
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at tissue samples from people who have a more aggressive form of splenic marginal zone lymphoma. It aims to better understand the genetic changes that happen when the disease transforms, which may help doctors predict and treat this condition in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have been diagnosed with transformed splenic marginal zone lymphoma (a more aggressive form)
- A tumor sample (from spleen, lymph node, or other site) taken at the time of transformation is available for testing
- Your medical records from diagnosis and follow-up are available for researchers to review
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects stored tissue samples (from skin or other needed procedures) from people with CTCL, Sézary syndrome, or lymphomatoid papulosis, especially when you are starting or changing treatment. It’s meant to help researchers learn more about these illnesses and may support future research.
This study is for people who were just diagnosed with marginal zone lymphoma (a slow-growing blood cancer) and haven't started treatment yet. Researchers will collect blood and tissue samples and follow you over time to learn more about the disease.
This study collects and analyzes tumor samples from people with nodal marginal zone lymphoma to better understand the disease and predict outcomes. It may help doctors characterize the lymphoma more accurately using clinical and lab information.
This study looks at the cells and genetics of MALT lymphoma, a type of slow-growing lymphoma. It aims to learn more about the disease and may help find better ways to treat it.
This study tests three different treatment combinations using new drugs (mosunetuzumab alone, or combined with zanubrutinib or polatuzumab vedotin) for marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to find which combination works best and is safest.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Hear when a new Transformed Splenic Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.